Skip to main content
. Author manuscript; available in PMC: 2011 Feb 1.
Published in final edited form as: Exp Neurol. 2009 Dec 4;221(2):329–334. doi: 10.1016/j.expneurol.2009.11.018

Figure 1. Zonisamide protects against MPTP-induced reductions in striatal TH, DA and DOPAC.

Figure 1

Mice were treated with zonisamide (Zonis) at 20, 10, 5, or 1 mg/kg i.p. or vehicle 15 min before each MPTP injection. Mice received 4 daily injections of MPTP (30 mg/kg/day s.c.) and were killed 7 days after the last treatment. Results are the mean ± SD from 3-5 mice/group (control n=4, zonisamide n=3, all other groups n=5). Analysis of the data by one-way ANOVA with post hoc testing revealed a significant effect for TH (F6 df5,20 = 52), DA (F7 df6,24 = 64) and DOPAC (F7 df6,24 = 23). aP<0.05 from control, bP<0.05 from MPTP group.